Rapport Therapeutics Inc

Despite a clear long-term uptrend, the recent blow-off top pattern and extreme overbought readings signal exhaustion and elevated risk of a sharp pullback. In a Stage 2 advancing environment with high transition risk to distribution, price rejection at the 9/21 EMA zone and lack of short-term support favor a bearish medium-term stance. We recommend selling now into the 9/21 EMA area to align with the emerging supply-driven pressure.

• ↑Consensus 'Moderate Buy' rating with $57.86 target implies ~42% upside.
• ↑One-year TSR of 223.7% boosted by Russell index inclusions.
• ↓Unprofitable status with negative earnings yield and profitability scores.